IND vs. NDA: Understanding the Difference in FDA Submissions

For drug developers, FDA approval is a long and complex journey. Two of the most important milestones on this path are the Investigational New Drug (IND) application and the New Drug Application (NDA). While both are critical submissions, they serve very different purposes.

‍

The IND is the “starting line,” allowing clinical trials to begin, while the NDA is the “finish line,” requesting FDA approval to market the drug. Understanding the distinction between these two submissions is essential for planning your regulatory strategy, timelines, and documentation needs.

‍

What Is an IND?

The Investigational New Drug (IND) application is a sponsor’s formal request to the FDA for authorization to begin clinical trials in humans.

Key characteristics:

• Purpose: To show that it is reasonably safe to test the drug in humans.

• Timing: Submitted after preclinical (animal/toxicology) studies and before first-in-human clinical trials.

• Content:
  
  • Preclinical Data: Animal pharmacology and toxicology studies. ‍
  • CMC Information: Manufacturing details to ensure quality and consistency of investigational drug supply. ‍
  • Clinical Protocols: Proposed study designs, investigator information, and safety monitoring plans.

• Regulatory Authority: FDA must review the IND within 30 days. If no clinical hold is issued, trials may proceed.

In short: an IND does not seek approval to market a drug, but rather permission to study it in people.

What Is an NDA?

The New Drug Application (NDA) is the formal request for FDA approval to market a drug in the U.S.

Key characteristics:

• Purpose: To demonstrate that the drug is safe and effective for its intended use.

• Timing: Submitted after all clinical trial phases (I–III) are complete.

• Content:
  
  • Clinical Data: Efficacy and safety results from human studies. ‍
  • CMC Section: Full details on commercial manufacturing, controls, and stability. ‍
  • Labeling: Proposed prescribing information for healthcare professionals and patients. ‍
  • Risk/Benefit Analysis: Justification that the therapeutic benefits outweigh the risks.

• Regulatory Authority: FDA (typically CDER) reviews the NDA under standard (10 months) or priority (6 months) timelines.

Unlike the IND, an NDA requests market approval—the final step before a new drug can be sold and prescribed.

‍

‍

Why the Difference Matters

Understanding where INDs and NDAs fit into the development continuum is critical:

• Strategic Planning: Early CMC decisions made for IND submissions can have long-term consequences when scaling up for the NDA.

• Documentation Needs: IND writing is focused on clarity and risk mitigation for early trials, while NDA writing is exhaustive, requiring detailed integration of years of data.

• Timelines and Resources: Mismanaging IND preparation can delay trial initiation; mismanaging NDA preparation can jeopardize market entry.

‍

The Role of Expert Regulatory Writing

Both INDs and NDAs demand precision, but the scope and complexity differ significantly.

• For INDs, writing teams must synthesize preclinical results, outline protocols, and present investigational CMC in a way that reassures regulators of patient safety.

• For NDAs, writers must transform vast datasets into a compelling, regulator-ready story of safety, efficacy, and quality.

At GLOBAL, our regulatory writers and consultants support sponsors across the full lifecycle—from first-in-human INDs to market-ready NDAs. With experience across therapeutic areas, we ensure that every submission communicates science clearly and meets FDA expectations.

‍

Conclusion

The IND and NDA are two pillars of the U.S. regulatory process, each with a distinct role: one enables the study of a new drug in humans, and the other secures approval to bring it to market. Recognizing their differences—and planning accordingly—can mean the difference between costly delays and a smooth path to approval.

GLOBAL’s team of regulatory experts can help you prepare both INDs and NDAs with precision, ensuring that your program stays on track from first trial to final approval.

Contact us today to learn how we can support your IND and NDA submissions.

‍